Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities
Pulmonary Pharmacology & Therapeutics · 2022-12 · 77 · 102170
DOI: 10.1016/j.pupt.2022.102170 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pulmonary Pharmacology & Therapeutics, 2022-12. Verfasst von Nidhi Nainwal. Beteiligte Einrichtung: Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Premnagar, Dehradun, Uttarakhand, 248007, India. Electronic address: nidhi.…. Hauptthemen laut MEDLINE: Virus Diseases, COVID-19 Drug Treatment. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Respiratory viral infections are the leading cause of death worldwide. The current pandemic of coronavirus infection (COVID-19) challenged human beings for the treatment and prevention of this respiratory viral infection since its outbreak in 2019. Despite advancements in the medical field, scientists were helpless to give timely treatment and protection against this viral infection. Several drugs, whether antiviral or not, were given to the patients to reduce mortality and morbidity rate. Vaccines from various pharmaceutical manufacturers are now available to give immunization against covid-19. Still, coronavirus is continuously affecting people in the form of variants after mutation. Each new variant increases the infection risk and forces scientists to develop some innovative and effective treatments for this infection. The virus uses the host's cell machinery to grow and multiply in numbers. Therefore, scientists are facing challenges to develop antivirals that stop the virus without damaging the host cells too. The production of suitable antivirals or vaccines for the new virus would take several months, allowing the strain to cause severe damage to life. Inhalable formulation facilitates the delivery of medicinal products directly to the respiratory system without causing unwanted side effects associated with systemic absorption. Scientists are focusing on developing an inhaled version of the existing antivirals for the treatment of respiratory infections. This review focused on the inhalable formulations of antiviral agents in various respiratory viral infections including the ongoing covid-19 pandemic and important findings of the clinical studies. We also reviewed repurposed drugs that have been given through inhalation in covid-19 infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Premnagar, Dehradun, Uttarakhand, 248007, India. Electronic address: nidhi.nainwal87@gmail.com.
Zitieren
APA
Nainwal, N. (2022). Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities. Pulmonary Pharmacology & Therapeutics, 77, 102170. https://doi.org/10.1016/j.pupt.2022.102170
Vancouver
Nainwal N. Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities. Pulmonary Pharmacology & Therapeutics. 2022;77:102170. doi:10.1016/j.pupt.2022.102170
BibTeX
@article{Nainwal2022,
author = {Nainwal, Nidhi},
title = {Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities},
journal = {Pulmonary Pharmacology & Therapeutics},
year = {2022},
volume = {77},
pages = {102170},
doi = {10.1016/j.pupt.2022.102170}
}
EUVIMED